Trial Profile
A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec in US
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Voretigene neparvovec (Primary)
- Indications Leber congenital amaurosis; Retinal dystrophies
- Focus Adverse reactions
- Sponsors Spark Therapeutics
- 28 Sep 2020 Planned End Date changed from 1 Jan 2029 to 1 Jun 2025.
- 28 Sep 2020 Planned primary completion date changed from 1 Jan 2029 to 1 Jun 2025.
- 14 May 2020 Status changed from recruiting to active, no longer recruiting.